TheraRadar

Pharma Intelligence, Simplified

Data updated: Mar 10, 2026

DURACLON

CLONIDINE HYDROCHLORIDE
Oncology Approved 1996-10-02
1
Indication
--
Phase 3 Trials
29
Years on Market

Details

Status
Prescription
First Approved
1996-10-02
Routes
INJECTION
Dosage Forms
INJECTABLE

Companies

Active Ingredient: CLONIDINE HYDROCHLORIDE

DURACLON Approval History

Loading approval history...

What DURACLON Treats

4 indications

DURACLON is approved for 4 conditions since its original approval in 1996. These indications span multiple therapeutic areas including oncology, immunology, and more.

  • Cancer
  • Neuropathic Pain
  • Somatic Pain
  • Visceral Pain
Source: FDA Label
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

Full development history with FDA approval milestones

Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

DURACLON FDA Label Details

Pro

Indications & Usage

FDA Label (PDF)

Duraclon is indicated in combination with opiates for the treatment of severe pain in cancer patients that is not adequately relieved by opioid analgesics alone. Epidural clonidine is more likely to be effective in patients with neuropathic pain than somatic or visceral pain (see Clinical Trials ). The safety of this drug product has only been established in a highly selected group of cancer patients, and only after an adequate trial of opioid analgesia. Other use is of unproven safety and is not recommended. In a rare patient, the potential benefits may outweigh the known risks (see WARNINGS ...

Want competitive intelligence?

See who's developing similar drugs and track their progress

View Pipeline Dashboard

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.